维普期刊资源整合服务平台（V6.5）

165篇 您的检索式：作者名="Tangen CM"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer显示文摘	Petrylak DP Tangen CM Hussain MH	2004	N Engl J Med2004，351，15：	1
2	Frailty in older adults: evidence for a phenotype显示文摘	Fried LP Tangen CM Walston J	2001	J Gerontol A Biol Sci Med Sci2001，56，3：	1
3	Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study显示文摘	Droff TB Flaig TB Tangen CM	2011	J Clin Oncol2011，29，：	1
4	Docetaxel and estramustine compared with mitoxan-trone and prednisone for advanced refractory prostate cancer显示文摘	Petrylak DP Tangen CM Hussain MH	2004	N Engl J Med2004，351，15：	1
5	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer显示文摘	Petrylak DP Tangen CM Hussain MH	2004	N Engl J Med2004，351，：	1
6	Depressive symptoms and risks of coro-nary heart disease and mortality in elderly Americans显示文摘	Ariyo AA Haan M Tangen CM	2000	Circulation2000，102，15：	1
7	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer显示文摘	Petrylak DP Tangen CM Hussain MH	2004	N Engl J Med2004，351，15：	1
8	Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer显示文摘	Grossman HB Natale RB Tangen CM	2003	N Engl J Med2003，349，9：	1
9	Frailty in older adults: evidence for a phenotype显示文摘	Fried LP Tangen CM Walston J	2001	J Gerontol A Biol Sci Med Sci2001，56，3：	1
10	Antiandrogen withdrawal in castrate-refractory prostate cancer:a southwest oncology group trial (SWOG 9426)显示文摘	SARTOR AO TANGEN CM HUSSAIN MH	2008	Cancer2008，112，11：	1
11	Intermit- tent versus continuous androgen deprivation in prostate cancer 显示文摘	HUSSAIN M TANGEN CM BETTEY DL	2013	N Engl J Med2013，368，14：	1
12	Doeetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer显示文摘	Petrylak DP Tangen CM Hussain MH	2004	N Engl J Med2004，351，15：	1
13	Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them 显示文摘	Tangen CM Jung JW	1998	Stat Med1998，17，1516：	1
14	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer显示文摘	PETRYLAK DP TANGEN CM HUSSAIN MH	2004	N Engl J Med2004，351，15：	1
15	Neoadjuvant chemo- therapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer 显示文摘	Grossman HB Natale RB Tangen CM	2003	N Engl J Med2003，349，：	1
16	Non-parametric covariance methods for incidence density analyses of time-to-event data from a randomized clinical trial and their complementary roles to proportional hazards regression 显示文摘	Koch GG	2000	Stat Med2000，19，8：	1
17	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer 显示文摘	PETRYLAK DP TANGEN CM HUSSAIN MH	2004	N Engl J Med2004，351，15：	1
18	Absolute prostate -specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)显示文摘	Hussain M Tangen CM Higano C	2006	J Clin Oncol2006，24，24：	1
19	The influence of finasteride on the development of prostate cancer显示文摘	Thompson IM Coodman PJ Tangen CM	2003	N Engl J Med2003，349，3：	1
20	Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial 显示文摘	THOMPSON IM Jr TANGEN CM PARADELO J	2006	JAMA2006，296，19：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示